The FCGR3A-p.Val176Phe replacement (rs396991, frequently referred as Val158Phe), which increases CD16A (FcγRIIIa) affinity for IgG (8), has been related to the clinical course of haematological, autoimmune and infectious diseases, and to monoclonal antibody therapy outcome (9–14). Here, FCGR3A is linked to infectious disease.